Results 11 to 20 of about 53,685 (285)

Experience in using levodopa-benserazide [PDF]

Неврология, нейропсихиатрия, психосоматика, 2015
Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova   +3 more
doaj   +2 more sources

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients

Cells, 2022
The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede   +3 more
doaj   +3 more sources

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Neuropsychiatric Disease and Treatment, 2008
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite ...
David J Brooks
doaj   +1 more source

Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications

Frontiers in Pharmacology
IntroductionWomen with Parkinson’s Disease (PD) have higher plasma exposure to levodopa and are particularly prone to developing complications during chronic levodopa therapy. However, there are no longitudinal studies focusing on differences in levodopa
Valeria Conti, Valeria Conti, Emanuela De Bellis, Graziamaria Corbi, Bruno Charlier, Bruno Charlier, Viviana Izzo, Viviana Izzo, Maria Claudia Russillo, Marianna Amboni, Marianna Amboni, Marina Picillo, Marina Picillo, Cesa Lorella Maria Scaglione, Ilaria Cani, Calogero Edoardo Cicero, Alessandra Nicoletti, Andrea Soricelli, Paolo Barone, Paolo Barone, Amelia Filippelli, Amelia Filippelli, Maria Teresa Pellecchia, Maria Teresa Pellecchia   +23 more
doaj   +2 more sources

Kaugelearenenud Parkinsoni tõve ravi levodopa-karbidopa intestinaalse geeli infusiooniga [PDF]

, 2023
Alates 2014. aastast on kaugelearenenud Parkinsoni tõvega patsientidel Eestis kasutatud ühe ravimeetodina levodopa-karbidopa intestinaalset infusiooni.
Pill, Helen, Taba, Pille, Krikmann, Ülle   +2 more
core   +1 more source

Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase

npj Parkinson's Disease, 2021
Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed
Anouke van Rumund, Lukas Pavelka, Rianne A. J. Esselink, Ben P. M. Geurtz, Ron A. Wevers, Brit Mollenhauer, Rejko Krüger, Bastiaan R. Bloem, Marcel M. Verbeek   +8 more
doaj   +1 more source

Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination

, 2005
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa.
Castro, A, Hernandez, B, Obeso, E J, Luquin, M R, Tolosa, E S, Vaamonde, J, Jenner, P, Pavon, N, Grandas, F, Marin, C, Valldeoriola, F, Linazasoro, G, Stochi, F, Macias, R, Gimenez-Roldan, S, Alvarez, L, Rodriguez-Oroz, M C, Rodriguez, M   +17 more
core   +5 more sources

Exploring the levodopa-paradox of freezing of gait in dopaminergic medication-naïve Parkinson’s disease populations

npj Parkinson's Disease, 2023
The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen, Tamine T. C. Capato, Sirwan K. L. Darweesh, Egberto R. Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes   +6 more
doaj   +1 more source

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease

Frontiers in Neurology, 2021
Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios, Natalia Palacios, Natalia Palacios, Anas Hannoun, Julie Flahive, Doyle Ward, Doyle Ward, Kelsey Goostrey, Anindita Deb, Kara M. Smith   +9 more
doaj   +1 more source

Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes

Frontiers in Neurology, 2021
Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li, Ying-mai Yang, Li-bo Li, Meng-yu Zhang, Yang-yu Huang, Jie Wang, Lin Wang, Xin-hua Wan   +7 more
doaj   +1 more source